Drugs / EB-G3B7-NK dual-target CAR-NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07500220 | Mar 2026 → Mar 2027 expected | hepatocellular carcinoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-G3B7-NK dual-target CAR-NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07500220 ↗ |
| Modality | Cell therapy | “Allogeneic donor-derived NK cells genetically modified to express a dual-target CAR” NCT07500220 ↗ |
| Route | Intravenous | “Administered intravenously after lymphodepletion” NCT07500220 ↗ |
| Target | CD276 | “dual-target CAR recognizing GPC3 and B7-H3/CD276” NCT07500220 ↗ |
| Target | GPC3 | “dual-target CAR recognizing GPC3 and B7-H3/CD276” NCT07500220 ↗ |